RAIN THERAPEUTICS INC.

(RAIN)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 24-06-2022
3.740 USD   +8.72%
23/06RAIN THERAPEUTICS INC. : JonesTrading Institutional Services nog altijd een koopadvies
MM
02/06RAIN THERAPEUTICS INC. : Roth Capital Partners herhaalt koopadvies
MM
31/05RAIN THERAPEUTICS INC. : Piper Sandler herhaalt koopadvies
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société RAIN THERAPEUTICS INC.
03/06RAIN THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
18/05Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical On..
AQ
04/05RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
04/05Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pr..
AQ
20/04Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Rece..
AQ
01/04Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the America..
AQ
03/03RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
03/03RAIN THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Highli..
PU
03/03RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
03/03Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highl..
AQ
24/02Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Hig..
AQ
08/02Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments
AQ
31/01Rain Therapeutics to Present at SVB Leerink Global Healthcare Conference
AQ
25/01Rain Therapeutics to Present at Upcoming Virtual Investor Conferences
AQ
05/01Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination..
GL
05/01Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination..
GL
2021Rain Therapeutics to Present at Upcoming Investor Conferences
GL
2021Rain Therapeutics, Inc. Added to the NASDAQ Biotechnology Index
AQ
2021Rain Therapeutics to Present at Upcoming Investor Conferences
AQ
2021Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-A..
GL
2021RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2021Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Pr..
PU
2021RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Pr..
AQ
2021Research and Development (R&D) Day Presentation - November 2021
PU
2021Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Mila..
AQ
2021Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Rece..
AQ
2021Rain Therapeutics Hosting Research and Development (R&D) Day
GL
2021RAIN THERAPEUTICS : Hosting Research and Development (R&D) Day
GL
2021RAIN THERAPEUTICS : Corporate Presentation - October 2021
PU
2021RAIN THERAPEUTICS : Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virt..
GL
2021RAIN THERAPEUTICS : to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual Internati..
AQ
2021Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Confere..
GL
2021Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conferenc..
GL
2021Rain Therapeutics Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleu..
GL
2021RAIN THERAPEUTICS : to Present at IASLC 2021 World Conference on Lung Cancer and Participa..
AQ
2021RAIN THERAPEUTICS : EXECUTIVE SEVERANCE PLAN (Form 8-K)
PU
2021RAIN THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
2021RAIN THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Highlights Recent Pr..
PU
2021RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021RAIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2021RAIN THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Highlights Recent Pr..
AQ
2021Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Rec..
GL
2021RAIN THERAPEUTICS : Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differen..
AQ
2021RAIN THERAPEUTICS : Announces Collaboration with Tempus for Genomic Analysis in Planned MD..
AQ
2021RAIN THERAPEUTICS : Announces Patient Referral Partnership for the Planned MDM2-Amplified ..
AQ
2021RAIN THERAPEUTICS : to Present at the Goldman Sachs 42nd Annual Global Healthcare Conferen..
AQ
2021RAIN THERAPEUTICS : Reports First Quarter 2021 Financial Results and Highlights Recent Pro..
PU
2021RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021RAIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2021RAIN THERAPEUTICS : Reports First Quarter 2021 Financial Results and Highlights Recent Pro..
AQ
2021RAIN THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021RAIN THERAPEUTICS : Appoints Robert Doebele, M.D., Ph.D. as President
AQ
2021RAIN THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..
AQ
Volgende evenement op RAIN THERAPEUTICS INC.